GSK to sell remaining 4.2% stake in Haleon
GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.
FTSE 100
8,084.61
17:04 20/12/24
n/a
n/a
FTSE 350
4,463.29
17:14 20/12/24
n/a
n/a
FTSE All-Share
4,421.11
17:04 20/12/24
n/a
n/a
GSK
1,320.00p
16:54 20/12/24
-0.15%
-2.00p
Haleon
381.10p
16:34 20/12/24
0.13%
0.50p
Pharmaceuticals & Biotechnology
19,761.12
17:14 20/12/24
0.06%
12.71
The pharmaceutical company will sell about 385m ordinary shares in consumer health business Haleon, which it spun off in July 2022.
GSK initially retained a 12.9% stake in Haleon, but has since sold stakes in May 2023, October 2023 and January 2024.
The final disposal will be conducted through a placing of ordinary shares to institutional investors. GSK said the offer price will be determined by means of an accelerated bookbuild offering process which will start immediately.